Response of human monocyte-derived dendritic cells to immunostimulatory DNA.
Activated dendritic cells (DC) are of key importance for the initiation of primary immune responses and represent promising tools for immunotherapies in humans. Since DNA containing CpG motifs have been described as potent immunostimulatory (IS) adjuvants for murine DC, we here studied maturation and stimulation of functional activity in human monocyte-derived DC (MODC) in response to several immunostimulatory oligodeoxynucleotides (IS-ODN) and plasmid DNA (IS-PL). We show that exposure of MODC to IS-PL, but not IS-ODN, induced a dose-dependent strong up-regulation of HLA class II and co-stimulatory molecules (CD80, CD86), similar to that observed after treatment with TNF-alpha. Functional activity was assessed by the detection of increased secretions of IL-6 and IL-12(p75) following treatment with IS-PL. In addition, IS-PL-stimulated MODC acquired a high T cell-stimulatory capacity. T cells stimulated by tetanus toxoid-pulsed, IS-PL-matured MODC were significantly more frequently IFN-gamma positive (25.2+/-2.7%) as compared to TNF-alpha-treated MODC (15.4+/-1.4%), indicating a strong activation of Th1 lymphocytes. In conclusion, we demonstrate that human MODC are activated by IS-PL but not IS-ODN previously used as adjuvants in animal models. The Th1-like immune response observed after stimulation with IS-PL-treated DC suggests that preincubation of human MODC with IS-PL or coimmunization with IS-PL may represent an useful approach to generate strongly activated human MODC for several therapeutic applications such as DC-based tumor immunotherapy.
Schattenberg
D
D
German Diabetes Research Institute, University of Düsseldorf.
Schott
M
M
Reindl
G
G
Krueger
T
T
Tschoepe
D
D
Feldkamp
J
J
Scherbaum
W A
WA
Seissler
J
J
D000276:Adjuvants, Immunologic; D015703:Antigens, CD / Q000096:biosynthesis; D051940:B7-2 Antigen; D002454:Cell Differentiation / Q000187:drug effects; D018899:CpG Islands; D004269:DNA, Bacterial / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D003851:Deoxyribonucleases / Q000494:pharmacology; D006681:HLA-D Antigens / Q000096:biosynthesis; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D016219:Immunotherapy, Adoptive; D018664:Interleukin-12 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D009000:Monocytes / Q000166:cytology / Q000187:drug effects; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D010957:Plasmids / Q000235:genetics; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000097802:CD83 Antigen
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D051940:B7-2 Antigen; D004269:DNA, Bacterial; D003851:Deoxyribonucleases; D006681:HLA-D Antigens; D007136:Immunoglobulins; D018664:Interleukin-12; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D009838:Oligodeoxyribonucleotides; D014409:Tumor Necrosis Factor-alpha; D000097802:CD83 Antigen; C497964:CD86 protein, human